High C-reactive protein is associated with the efficacy of neoadjuvant chemotherapy for hormone receptor-positive breast cancer
- PMID: 39612416
- PMCID: PMC11608662
- DOI: 10.1097/MD.0000000000040775
High C-reactive protein is associated with the efficacy of neoadjuvant chemotherapy for hormone receptor-positive breast cancer
Abstract
C-reactive protein (CRP) is a nonspecific biomarker for systemic inflammatory response and is linked to the prognosis of breast cancer (BC); however, few studies have investigated the correlation between CRP and the effectiveness of neoadjuvant chemotherapy treatment for BC. We recruited 177 patients with BC who underwent neoadjuvant chemotherapy in our clinical trial. the median CRP level (0.24 mg/L), patients were categorized into high and low groups. We examined the relationship between CRP levels and various clinicopathological factors, including pathological complete response (pCR), using the chi-square test or Fisher exact test. Furthermore, we evaluated the predictive capacity of CRP for different molecular subtypes by constructing receiver operating characteristic curves. To identify the independent variables associated with pCR, we conducted logistic regression multivariate analysis. No association was found between C-reactive levels at baseline and pCR rates. CRP level was significantly associated with higher body mass index, and the high CRP group had more overweight patients (47.06% vs. 16.30%, P < .001). In hormone receptor-positive patients, the high CRP group demonstrated a significantly higher pCR rate (OR = 4.115, 95% CI: 1.481-11.36, P = .009). The areas under the curve was 0.670 (95% CI: 0.550-0.792, P < .001). Multivariate logistic analysis showed that the CRP level was a significant independent predictor of pCR (OR = 5.882, 95% CI: 1.470-28.57, P = .017). High CRP levels were found to be associated with a higher pCR rate, indicating their independent predictive value in determining the efficacy of neoadjuvant chemotherapy in hormone receptor-positive BC patients.
Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.
Conflict of interest statement
The authors have no conflicts of interest to disclose.
Figures



Similar articles
-
Serum Tumor Marker Levels might have Little Significance in Evaluating Neoadjuvant Treatment Response in Locally Advanced Breast Cancer.Asian Pac J Cancer Prev. 2015;16(11):4603-8. doi: 10.7314/apjcp.2015.16.11.4603. Asian Pac J Cancer Prev. 2015. PMID: 26107211
-
The Systemic Immune-Inflammation Index is a Predictor of Chemotherapy Sensitivity and Disease-Free Survival in Patients With Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.Clin Breast Cancer. 2025 Feb;25(2):e190-e195. doi: 10.1016/j.clbc.2024.09.016. Epub 2024 Oct 1. Clin Breast Cancer. 2025. PMID: 39448293
-
On-treatment biopsies to predict response to neoadjuvant chemotherapy for breast cancer.Breast Cancer Res. 2024 Sep 24;26(1):138. doi: 10.1186/s13058-024-01883-w. Breast Cancer Res. 2024. PMID: 39317942 Free PMC article. Clinical Trial.
-
Neoadjuvant Chemotherapy and Pathologic Complete Response in HR+/HER2- Breast Cancer: Impact of Tumor Ki67 and ER Status.Chemotherapy. 2024;69(3):141-149. doi: 10.1159/000537874. Epub 2024 Feb 16. Chemotherapy. 2024. PMID: 38368871
-
Predictive value of pretreatment circulating inflammatory response markers in the neoadjuvant treatment of breast cancer: meta-analysis.Br J Surg. 2024 May 3;111(5):znae132. doi: 10.1093/bjs/znae132. Br J Surg. 2024. PMID: 38801441 Free PMC article.
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous